- |||||||||| AdCOVID (COVID-19 vaccine) / Altimmune, The University of Alabama
Preclinical, Journal: The role of vaccination route with an adenovirus-vectored vaccine in protection, viral control, and transmission in the SARS-CoV-2/K18-hACE2 mouse infection model. (Pubmed Central) - Sep 7, 2023 Utilizing a replication-deficient adenovirus serotype 5-vectored vaccine expressing the SARS-CoV-2 RBD (AdCOVID) in homozygous and heterozygous transgenic K18-hACE2, we investigated the impact of the route of administration on vaccine immunogenicity, SARS-CoV-2 transmission, and survival...Notably, in a novel transmission model, intranasal vaccination reduced viral transmission to na
- |||||||||| AdCOVID (COVID-19 vaccine) / Altimmune, The University of Alabama
Trial completion, Trial completion date: Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study) (clinicaltrials.gov) - Aug 14, 2023 P1, N=92, Completed, Utilizing a replication-deficient adenovirus serotype 5-vectored vaccine expressing the SARS-CoV-2 RBD (AdCOVID) in homozygous and heterozygous transgenic K18-hACE2, we investigated the impact of the route of administration on vaccine immunogenicity, SARS-CoV-2 transmission, and survival...Notably, in a novel transmission model, intranasal vaccination reduced viral transmission to na Active, not recruiting --> Completed | Trial completion date: Feb 2022 --> Dec 2022
- |||||||||| AdCOVID (COVID-19 vaccine) / Altimmune, The University of Alabama
The role of vaccination route with an adenovirus-vectored vaccine in protection, viral control, and transmission in the SARS-CoV-2/K18-hACE2 mouse infection model (Convention Center - Hall 4A (4th Floor); In-Person-Only) - Oct 9, 2022 - Abstract #ASTMH2022ASTMH_736; Utilizing a replication-deficient adenovirus serotype 5-vectored vaccine expressing the SARS-CoV-2 RBD (AdCOVID) in the K18-human ACE2 mouse model, we investigated the impact of route of administration on vaccine immunogenicity, survival, and transmission...Overall, our data provides further evidence for the utility of IN vaccination in protecting against SARS-CoV-2 infection and transmission. Additional studies exploring the mechanism surrounding enhanced protection afforded by IN vaccination are needed.
- |||||||||| AdCOVID (COVID-19 vaccine) / Altimmune, The University of Alabama
Enrollment closed, Enrollment change: Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study) (clinicaltrials.gov) - Jul 14, 2021 P1, N=92, Active, not recruiting, These data show that AdCOVID promotes concomitant systemic and mucosal immunity and represents a promising vaccine candidate. Recruiting --> Active, not recruiting | N=180 --> 92
- |||||||||| AdCOVID (COVID-19 vaccine) / Altimmune, The University of Alabama
Clinical, Clinical guideline, Review, Journal: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. (Pubmed Central) - May 11, 2021 Herein, we provide operational COVID-19 vaccine guidance for patients participating in oncology clinical trials. In our perspective, continued quality oncological care requires that patients with cancer, including those involved in trials, be prioritized for COVID-19 vaccination, which should not affect trial eligibility.
- |||||||||| AdCOVID (COVID-19 vaccine) / Altimmune, The University of Alabama
Journal: COVID-19 Vaccine Acceptance among College Students: A Theory-Based Analysis. (Pubmed Central) - May 7, 2021 The model accounted for 60.6% of the variance in intention to take the COVID-19 vaccine. This study provides evidence for the utility of MTM as a timely intervention to design messages for college students to enhance COVID-19 vaccine acceptability.
- |||||||||| AdCOVID (COVID-19 vaccine) / Altimmune, The University of Alabama
Enrollment open: Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study) (clinicaltrials.gov) - Feb 23, 2021 P1, N=180, Recruiting, This study provides evidence for the utility of MTM as a timely intervention to design messages for college students to enhance COVID-19 vaccine acceptability. Not yet recruiting --> Recruiting
|